Thérapie médicamenteuse de la dépression: apports et limites des dosages plasmatiques de tricycliques [Drug therapy of depression: benefits and limits of blood levels of tricyclic antidepressants]

Détails

ID Serval
serval:BIB_392CC5196F91
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Thérapie médicamenteuse de la dépression: apports et limites des dosages plasmatiques de tricycliques [Drug therapy of depression: benefits and limits of blood levels of tricyclic antidepressants]
Périodique
Schweizerische medizinische Wochenschrift
Auteur⸱e⸱s
Baumann P.
ISSN
0036-7672 (Print)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
14/02/1981
Peer-reviewed
Oui
Volume
111
Numéro
7
Pages
228-239
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Résumé
The introduction of sensitive methods has rendered possible a multitude of studies on the relationship between plasma levels of tricyclics and their clinical effectiveness. However, there are conflicting reports concerning the existence of a "therapeutic window" for the usual antidepressives such as amitriptyline, nortriptyline, chlorimipramine, imipramine, desipramine and maprotiline. The dosage is not indicated routinely but may provide useful hints when the patient does not respond to treatment or does not take the prescribed medication regularly (non-compliance). Plasma measurements of tricyclics have served to investigate the interaction of other drugs, the advantages of single or multiple dosage, the influence of the patient's age and sex and the existence of active metabolites. Other questions have been raised concerning the real efficacy of the drugs, and also concerning the type of depression which responds to this treatment.
Mots-clé
Antidepressive Agents, Tricyclic/blood, Antidepressive Agents, Tricyclic/therapeutic use, Biotransformation, Delayed-Action Preparations, Depression/drug therapy, Dose-Response Relationship, Drug, Half-Life, Humans
Pubmed
Web of science
Création de la notice
11/01/2021 12:34
Dernière modification de la notice
04/05/2023 6:52
Données d'usage